What is the total potential value of Bayer's acquisition of Perfuse Therapeutics, and how is the payment structured?

The deal has a potential value of up to $2.45 billion, consisting of a $300 million upfront payment and additional development, regulatory, and commercial milestone payments contingent on success criteria.

Why is Bayer acquiring Perfuse Therapeutics, according to the announcement?

Bayer stated it is acquiring Perfuse Therapeutics to complement its ophthalmology pipeline.

Bayer to buy Perfuse Therapeutics in up to $2.45 billion deal

May 5, 2026

Bayer announced plans to acquire biopharmaceutical firm Perfuse Therapeutics for up to $2.45 billion to bolster its ophthalmology pipeline. The deal includes a $300 million upfront payment plus additional milestone payments based on success criteria.

reuters

2026-05-05

Bayer to buy Perfuse Therapeutics in up to $2.45 billion deal

2026-06-30

Bayer Seeks US Duties on Chinese-Made Glyphosate, Angering Farmers

2026-07-01

Bayer shifts US glyphosate business to Ruveon after seeking tariffs on Chinese imports

Bayer to buy Perfuse Therapeutics in up to $2.45 billion deal

FAQ